Javed Butler
Advanced Heart Failure and Transplant Cardiology · Jackson, MSNPI 1639100928
Payments from drug & device makers
Across 1,409 payments — averaging $2906.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim International GmbH$737K
- Impulse Dynamics (USA) Inc.$594K
- Merck$472K
- Vifor (international) Ltd.$363K
- Boehringer Ingelheim$205K
- AstraZeneca$197K
- plus $1.5M from 54 others
Across 79 payments — averaging $4196.52 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis Pharma AG$114K
- Medtronic$66K
- Novo Nordisk AS$41K
- Boehringer Ingelheim International GmbH$33K
- American Regent$25K
- Novartis$21K
- plus $31K from 4 others
What the payments were for
- Consulting fees$2,757,07067%
- Speaking & faculty fees$906,63322%
- Travel & lodging$408,43410%
- Food & beverage$22,1691%
- Education$3000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim International GmbH | 150 | $736,968 |
| Impulse Dynamics (USA) Inc. | 65 | $594,375 |
| Merck | 272 | $471,937 |
| Vifor (international) Ltd. | 42 | $363,090 |
| Boehringer Ingelheim | 117 | $205,234 |
| AstraZeneca | 103 | $196,929 |
| Boehringer Ingelheim RCV GmbH & Co KG | 31 | $128,933 |
| Novartis | 68 | $121,257 |
| Bayer | 71 | $119,327 |
| Anumana, Inc. | 3 | $99,000 |
| Novo Nordisk | 37 | $84,653 |
| Lilly USA, LLC | 32 | $73,714 |
| Edwards Lifesciences | 38 | $65,208 |
| Boehringer Ingelheim Singapore Pte. Ltd. | 12 | $52,866 |
| Boehringer Ingelheim Canada Ltd.ltee | 16 | $47,489 |
| Novo Nordisk AS | 15 | $47,416 |
| Roche Diagnostics International Ltd | 11 | $47,075 |
| Boehringer Ingelheim (phil.) Inc. | 10 | $46,990 |
| Amgen | 21 | $41,473 |
| Abbott | 33 | $36,626 |
| Astrazeneca UK Limited | 15 | $35,729 |
| Eli Lilly | 21 | $34,811 |
| Novartis Pharma AG | 9 | $33,305 |
| Johnson & Johnson | 19 | $32,638 |
| Lexicon Pharmaceuticals, Inc. | 7 | $31,301 |
| Pharmacosmos Therapeutics Inc. | 3 | $28,244 |
| Vifor Pharma, Inc. | 18 | $23,073 |
| E.r. Squibb & Sons, L.L.C. | 10 | $22,880 |
| Boehringer Ingelheim Hong Kong Ltd. | 3 | $20,000 |
| Vifor Fresenius Medical Care Renal Pharma Ltd. | 7 | $19,127 |
| Janssen Scientific Affairs, LLC | 12 | $14,021 |
| Sanofi-aventis U.S. LLC | 3 | $13,823 |
| Idorsia Pharmaceuticals US Inc | 3 | $13,520 |
| Boehringer Ingelheim MENA (scientific Office) Fz-llc | 4 | $13,250 |
| Boehringer Ingelheim Malaysia Sdn. Bhd. | 3 | $13,214 |
| Pfizer | 8 | $12,297 |
| Boehringer Ingelheim, Unipessoal, Lda. | 1 | $12,000 |
| Cvrx, Inc. | 6 | $11,725 |
| Boehringer Ingelheim Norway KS | 1 | $11,050 |
| Roche Diagnostics Corporation | 8 | $9,218 |
| Recordati_rare_diseases_inc. | 4 | $8,321 |
| ZOLL Circulation Inc | 6 | $7,738 |
| Boehringer Ingelheim Do Brasil Quimica E Farmaceutical Ltda. | 2 | $7,380 |
| Boehringer Ingelheim Mexico SA De CV | 2 | $6,400 |
| Baxter Healthcare | 6 | $6,045 |
| Boehringer Ingelheim South Africa (pty) Ltd | 2 | $6,000 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 2 | $5,850 |
| Regeneron | 6 | $5,741 |
| Applied Therapeutics, Inc. | 7 | $5,400 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $5,160 |
| Livanova USA, Inc. | 9 | $4,500 |
| Boehringer Ingelheim Israel Ltd. | 1 | $4,440 |
| Boehringer Ingelheim S.A. | 2 | $4,400 |
| Scpharmaceuticals Inc. | 2 | $4,000 |
| Nippon Boehringer Ingelheim Co., Ltd. | 1 | $3,900 |
| Boston Scientific | 4 | $3,654 |
| Gilead | 3 | $3,603 |
| Medtronic(2 entities) | 23 | $3,559 |
| Boehringer Ingelheim Del Ecuador Cia. Ltda. | 1 | $3,170 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $3,000 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$1,081,488
- OPTIMIZER$798,584
- VERQUVO$340,859
- Veltassa$320,622
- OPTIMIZER SMART SYSTEM$192,512
- ENTRESTO$116,150
- FARXIGA$90,251
- ECG-AI LEF$88,000
- Non-Covered$59,939
- Kerendia$58,116
- INVOKANA$41,499
- LCZ696B_ENTRESTO_CARDIOVASCULAR$33,132
- MK-1242$29,173
- Monoferric$28,244
- MitraClip$17,230
- Victoza$17,065
- MULTAQ$13,823
- LOKELMA$13,157
- PRADAXA$12,000
- Barostim Neo System$11,725
How this compares
Too few advanced heart failure and transplant cardiology providers in Mississippito place this figure against a meaningful peer group, so we don't.
Other advanced heart failure and transplant cardiology in Jackson
- Robert LongJackson$1.7M
- Lampros PapadimitriouJackson$224K
- Brandon LennepJackson$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.